A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina (STELLA).

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of Pletaal (Cilostazol) in Subjects With Vasospastic Angina (STELLA).

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Cilostazol (Primary)
  • Indications Variant angina pectoris
  • Focus Therapeutic Use
  • Acronyms STELLA
  • Sponsors Korea Otsuka Pharmaceutical
  • Most Recent Events

    • 04 Sep 2013 Primary endpoint 'Angina-pectoris-event-rate' has been met according to results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 04 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 13 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top